Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 22: FIDELITY: Finerone in Pts With Chronic Kidney Disease
Author(s): Gerasimos Filippatos Added: 1 year ago
ESC Congress 22 — Prof Gerasimos Filippatos joins us onsite at ESC to discuss the findings of the FIDELITY study, which pooled the findings of FIDELIO-DKD and FIGARO-DKD to evaluate the impact of finerenonein addition to standard care in reducing the risk of cardiovascular and renal outcomes in adult patients with chronic kidney disease (CKD). Over 13,000 patients from 48 countries were included… View more

Prevention & Chronic Conditions

CV Disease in Special Populations
Statins: Practical Considerations – A Review
Author(s): Kazeen Abdullah , Anand Rohatgi Added: 3 years ago
Statins are currently the most efficacious and widely prescribed lipid-lowering medications.1 Numerous randomised controlled trials across a spectrum of baseline atherosclerotic cardiovascular disease (ASCVD) risk show that a 1.0 mmol/L (~40 mg/dL) reduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy is associated with an overall 21 % reduction in major vascular events and… View more

Standards & Guidelines

Prevention & Chronic Conditions
New Challenges in the Management of Heart Failure
Author(s): Juan Carlos Kaski , Giuseppe Rosano , Theresa A McDonagh , et al Start date: Nov 05, 2020

Heart Failure
Author(s): Dimitrios Bliagos , Ajay J Kirtane , Jeffrey W Moses Added: 3 years ago
Worldwide, it is estimated that the total number of people with diabetes will increase from 171 million in 2000 to 366 million in 2030.1 In the US, a total of 23.6 million people have diabetes, representing 7.8% of the population, and the prevalence of diabetes is on the rise, due to an increasingly sedentary lifestyle, increasing obesity and an ageing population. These statistics do not account… View more

Prevention & Chronic Conditions

MI/ACS
Author(s): Juan Tamargo Added: 3 years ago
Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1–5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6–8 The prevalence of T2D among patients with HF is as high as 40–45% and that of HF in patients with… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Roland E Schmieder Added: 3 years ago
The primary goal in the treatment of hypertensive patients is to achieve the maximum possible reduction in the long-term total risk of cardiovascular (CV) and renal morbidity and mortality. In addition to the lowering of blood pressure (BP) per se, successful realisation of the primary goal of treatment also requires appropriate consideration of co-morbidities.1–3 Although there is some… View more

Prevention & Chronic Conditions
Ioanna Gouni-Berthold
Job title: Professor of Internal Medicine
Prof Ioanna Gouni-Berthold is Professor of Internal Medicine and Head of the Lipid Research Clinic at the Policlinic for Endocrinology, Diabetes and Preventive Medicine at the University of Cologne in Germany. Prof Gouni-Bertholdreceived her training at prestigious Universities such as the Baylor College of Medicine and Harvard Medical School and is double board certified in Internal Medicine… View more
Giulia Ferrannini
Research Area(s) / Expertise:

Diabetes

 Job title: PHD Fellow
Dr Giulia Ferrannini is a specialist in internal medicine and a researcher at the Karolinska Hospital. Her research focusses on screening for diabetes and glucose disorders. Dr Ferrannini studied medicine at University of Modena and Reggio Emilia in Italy. She then went on to study as a research fellow at the Naomi Berrie Diabetes Center at Columbia University in New York in 2014, before… View more
Author(s): Alejandro de la Sierra Added: 3 years ago
The Concepts of Metabolic Syndrome and Cardiometabolic Risk Cardiometabolic risk represents a situation where the possibilities of developing atherosclerotic cardiovascular disease and diabetes are significantly enhanced as a consequence of the presence of insulin resistance and atherogenic dyslipidaemia. Dyslipidaemia is characterised by the presence of low high-density lipoprotein (HDL)… View more

Prevention & Chronic Conditions
SGLT-2 Inhibitors and Cardio-renal Outcomes
Author(s): Shelley Zieroth , , Added: 2 years ago
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) andProf Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice. This three-part series, 'SGLT-2 Inhibitors and Cardio-renal… View more

Heart Failure

Prevention & Chronic Conditions